Cefuroxime axetil (oral): Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 26: Line 26:
'''| [[Cefuroxime axetil overdosage|Overdosage]]'''
'''| [[Cefuroxime axetil overdosage|Overdosage]]'''
'''| [[Cefuroxime axetil dosage and administration|Dosage and Administration]]'''
'''| [[Cefuroxime axetil dosage and administration|Dosage and Administration]]'''
'''| [[Cefuroxime axetil compatibility and stability|Compatibility and Stability]]'''
'''| [[Cefuroxime axetil clinical studies|Clinical Studies]]'''
'''| [[Cefuroxime axetil how supplied|How Supplied]]'''
'''| [[Cefuroxime axetil how supplied|How Supplied]]'''
'''| [[Cefuroxime axetil labels and packages|Labels and Packages]]'''
'''| [[Cefuroxime axetil labels and packages|Labels and Packages]]'''

Revision as of 04:50, 6 January 2014

Cefuroxime axetil
CEFTIN® FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Overdosage
Dosage and Administration
How Supplied
Clinical Studies
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Abdurahman Khalil, M.D. [2]

Overview

Cefuroxime axetil is a second generation oral cephalosporin antibiotic. It was discovered by Glaxo now GlaxoSmithKline and introduced in 1987 asZinnat.[1] It was approved by FDA on Dec 28, 1987.[2] It is available by GSK as Ceftin in US

It is an acetoxyethyl ester prodrug of cefuroxime which is effective orally.The activity depends on in vivo hydrolysis and release of cefuroxime.

Category

Cephalosporins, second generation.

US Brand Names

CEFTIN®

FDA Package Insert

Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Overdosage | Dosage and Administration | Clinical Studies | How Supplied | Labels and Packages

References

http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/050605s042lbl.pdf